Headline News

The NIH announced the beginning of a phase 1 first-in-human trial of a vaccine for Lassa fever, a potentially fatal viral hemorrhagic disease for which there is no approved vaccine or treatment.

Researchers developed a wearable jumpsuit with sensors that can objectively measure an infant’s gross motor development and, with the help of AI, identify milestones with more than 90% accuracy, according to findings reported in Pediatrics.

One question that freshly matriculated medical students become well-versed in answering is “what specialty are you interested in?”

ATHENS, Greece — In patients who have previously undergone corneal refractive surgery, the asymmetric segmental design of the Acunex VarioMax and Lentis Mplus IOLs is an ideal solution, according to a presenter at the ESCRS winter meeting.

Alnylam announced the FDA approval of its supplemental new drug application for vutrisiran, an RNA interfering small molecule transthyretin stabilizer, for the treatment of transthyretin amyloidosis with cardiomyopathy.

The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous induction options for the treatment of moderately to severely active Crohn’s disease, Johnson & Johnson reported.

Cataracts are the leading cause of blindness in adults older than age 50 worldwide.

The contraction inhibitor atosiban prolonged labor in cases of threatened preterm birth beyond 30 weeks’ gestation but did not improve neonatal outcomes compared with placebo, researchers reported in The Lancet.

As cornea specialists, we talk a lot about how to get timely referrals of keratoconus patients from optometrists and ophthalmologists who don’t perform cross-linking. But it is also important to recognize our role in transitioning the patient back to the referring doctor. To me, there are three key elements of a successful handoff.